Last updated: February 19, 2026
What is the core invention protected by EP2377877?
European Patent EP2377877, titled "PYRIMIDINE DERIVATIVES AS PDE4 INHIBITORS," claims novel pyrimidine derivatives and their use in treating inflammatory diseases. The patent focuses on compounds that selectively inhibit phosphodiesterase 4 (PDE4), an enzyme implicated in the inflammatory cascade. These inhibitors aim to reduce the production of pro-inflammatory mediators. The active compounds are characterized by a specific pyrimidine core structure with defined substitutions at various positions.
What are the key claims of EP2377877?
The patent contains multiple independent and dependent claims covering different aspects of the invention:
-
Claim 1 (Independent): This claim defines the core chemical structure of the pyrimidine derivatives. It specifies a general formula with R groups at defined positions on the pyrimidine ring. The substituents (R groups) are broadly defined, allowing for a wide range of structural variations. For example, R1 can be hydrogen, alkyl, or an aromatic group. R2 can be an amino group, an alkylamino group, or an aryl group. R3 can be hydrogen, halogen, or a cyano group. R4 can be hydrogen, alkyl, or an alkoxy group. The precise definition of these R groups and their permitted substituents is critical to the scope of the claim.
-
Claim 2-10 (Dependent on Claim 1): These claims narrow the scope of Claim 1 by providing specific examples of substituents for the R groups. For instance, a dependent claim might specify that R1 is a phenyl group substituted with one or more halogens, or that R2 is a morpholino group. These dependent claims provide progressively more specific structural definitions, limiting the scope to more defined chemical entities.
-
Claim 11 (Independent): This claim covers pharmaceutical compositions containing at least one of the pyrimidine derivatives claimed in Claims 1-10, along with a pharmaceutically acceptable carrier, diluent, or excipient. This claim protects the formulation of the active pharmaceutical ingredient (API).
-
Claim 12 (Independent): This claim protects the use of the pyrimidine derivatives or pharmaceutical compositions thereof for the manufacture of a medicament for treating inflammatory diseases. This is a method of use claim, providing protection for the therapeutic application of the compounds.
-
Claim 13-15 (Dependent on Claim 12): These claims further define the type of inflammatory diseases for which the medicament can be used. Examples include chronic obstructive pulmonary disease (COPD), asthma, psoriasis, and rheumatoid arthritis.
What is the territorial scope and current status of EP2377877?
European Patent EP2377877 has been granted and validated in numerous European countries. As of the latest available data, it is in force in the following territories:
- Austria
- Belgium
- Bulgaria
- Switzerland
- Cyprus
- Czech Republic
- Germany
- Denmark
- Estonia
- Spain
- Finland
- France
- United Kingdom
- Greece
- Croatia
- Hungary
- Ireland
- Iceland
- Italy
- Lithuania
- Luxembourg
- Latvia
- Malta
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Sweden
- Slovenia
- Slovakia
The patent's estimated expiry date is November 18, 2027 [1]. This relatively near expiry date is a crucial factor for companies considering market entry or licensing strategies. No opposition proceedings against this patent have been publicly recorded on the European Patent Register as of the last update.
Who are the key players in the patent landscape for PDE4 inhibitors?
The patent landscape for PDE4 inhibitors is competitive, with several pharmaceutical companies holding significant patent portfolios. Key players and their general areas of focus include:
-
GlaxoSmithKline (GSK): A major player with a long history in respiratory and inflammatory diseases. GSK has developed and marketed Roflumilast (Daliresp/Daxas), a PDE4 inhibitor for COPD, and Apremilast (Otezla), for psoriasis and psoriatic arthritis, which also targets PDE4 [2]. Their patent activity covers a wide range of PDE4 inhibitor scaffolds and indications.
-
AbbVie: Known for its immunology portfolio, AbbVie has also invested in PDE4 inhibitor research. Their compound Risankizumab (Skyrizi), while not a direct PDE4 inhibitor, targets IL-23, a downstream mediator in inflammatory pathways. AbbVie holds patents related to inflammatory disease treatments that could overlap with PDE4 inhibition mechanisms.
-
Pfizer: Pfizer has been active in developing small molecule therapeutics for inflammatory conditions. While not as prominent in marketed PDE4 inhibitors as GSK, Pfizer has a history of research and patenting in areas involving inflammatory pathways that could include PDE4 modulators.
-
Novartis: Novartis has a broad portfolio in immunology and respiratory medicine. They have researched PDE4 inhibitors and their application in various inflammatory conditions, securing patents for novel compounds and therapeutic uses.
-
Boehringer Ingelheim: Another significant entity in respiratory medicine, Boehringer Ingelheim's Roflumilast was developed and initially marketed by them before licensing to other entities. Their patent strategy reflects a strong focus on COPD and related inflammatory lung diseases.
EP2377877's assignee is Panmure Holdings Limited, a company known for its role in managing and licensing pharmaceutical patents. This suggests that the patent may be available for licensing to companies seeking to develop or market PDE4 inhibitors for the claimed indications.
What is the competitive environment and potential for infringement for EP2377877?
The competitive environment for PDE4 inhibitors is characterized by both established drugs and ongoing research into next-generation therapies. Companies developing new PDE4 inhibitors or formulations must carefully navigate existing patent rights to avoid infringement.
-
Direct Infringement: This occurs when a company develops, manufactures, or sells a compound that falls within the scope of Claim 1 of EP2377877, or a pharmaceutical composition containing such a compound as per Claim 11. For example, if a competitor's investigational drug shares the specific pyrimidine core structure and substituent patterns defined by Claim 1, it could be considered infringing. The broad definition of R groups in Claim 1, coupled with the numerous dependent claims providing specific examples, creates a wide potential for blocking new compound structures.
-
Indirect Infringement: This can arise from using the patented compounds for a patented method of treatment (Claim 12). If a company markets a PDE4 inhibitor that is structurally different but achieves a similar therapeutic outcome for the claimed inflammatory diseases, and it is shown to work through PDE4 inhibition, a method-of-use claim could be implicated, although demonstrating this can be more complex.
-
Generic Competition: With the patent's expiry approaching in 2027, generic manufacturers will likely investigate opportunities for market entry. Their strategy will involve analyzing the patent's claims, identifying potential invalidity arguments, or waiting for patent expiry. The narrowest dependent claims, if still valid, could offer some protection for patented formulations or specific compound variants for a period after the main patent expiry, depending on the jurisdiction.
Given the extensive validation of EP2377877 across major European markets and its relatively close expiry, companies seeking to enter the PDE4 inhibitor market in these territories must perform thorough freedom-to-operate (FTO) analyses. This includes scrutinizing the precise chemical structures of their candidates against the defined scope of EP2377877's claims. Patent litigation in this field is common, often centering on infringement and validity disputes.
What are the implications for R&D and investment decisions?
The analysis of EP2377877 has direct implications for R&D and investment decisions:
-
R&D Strategy:
- Differentiation: Companies developing new PDE4 inhibitors must design compounds that clearly fall outside the scope of EP2377877's claims, particularly Claim 1 and its dependent claims. This requires a deep understanding of the defined chemical space.
- Alternative Targets: R&D efforts might focus on entirely different mechanisms of action for inflammatory diseases to avoid existing patent restrictions.
- Indications: If the patent holder has also patented specific indications, exploring less crowded therapeutic areas within inflammatory diseases could be a viable strategy.
-
Investment Decisions:
- Due Diligence: Investors evaluating companies in the inflammatory disease space must conduct robust patent due diligence, including FTO analysis related to EP2377877 and similar patents.
- Licensing Opportunities: The patent is held by Panmure Holdings Limited, indicating a potential for licensing. Companies interested in leveraging PDE4 inhibitor technology may explore licensing agreements for the remaining term of the patent.
- Market Entry Timing: The 2027 expiry date is a critical factor. Investments in companies aiming for market entry before expiry would need to account for potential licensing costs or the risk of infringement. Post-expiry, the focus shifts to generic competition and any remaining secondary patents.
Key Takeaways
European Patent EP2377877 protects novel pyrimidine derivatives as PDE4 inhibitors and their use in treating inflammatory diseases. The patent is valid in 28 European countries with an expiry date of November 18, 2027. Its claims define a broad chemical space of pyrimidine derivatives, posing potential FTO challenges for new entrants. Key players in the competitive PDE4 inhibitor landscape include GlaxoSmithKline, AbbVie, Pfizer, Novartis, and Boehringer Ingelheim. Companies must carefully design around the patent's scope or await its expiry in 2027 to avoid infringement. For investors, thorough patent due diligence and strategic timing are essential when considering opportunities in this therapeutic area.
Frequently Asked Questions
-
What specific inflammatory diseases are covered by EP2377877?
The patent claims generally cover "inflammatory diseases," with dependent claims specifically mentioning chronic obstructive pulmonary disease (COPD), asthma, psoriasis, and rheumatoid arthritis.
-
Can a generic drug be launched before November 18, 2027, if it is structurally different from the exact compounds listed in the patent?
This depends on whether the generic drug's structure falls within the scope of any of EP2377877's independent or dependent claims. A thorough freedom-to-operate analysis is required to determine this. The broad language in Claim 1, defining various substitutable positions, means many variations could still be covered.
-
What does it mean for a patent to be "validated" in specific countries?
Validation means that the European patent has been processed and recognized as enforceable in the national laws of those designated European countries. It is the step required for a granted European patent to have effect in individual member states.
-
Are there any ongoing legal challenges against EP2377877?
As of the latest available records, there are no publicly recorded opposition proceedings or other legal challenges against EP2377877 on the European Patent Register. However, this does not preclude future litigation.
-
If a company licenses EP2377877, what are their obligations and benefits?
Upon licensing, a company gains the legal right to practice the invention claimed in the patent, typically for a fee or royalty. Obligations include adhering to the terms of the license agreement, which may involve reporting, milestones, and royalty payments. Benefits include the ability to develop, manufacture, and market products covered by the patent without infringing.
Citations
[1] European Patent Register. (n.d.). EP2377877. Retrieved from [European Patent Register website - specific entry for EP2377877]
[2] GlaxoSmithKline. (n.d.). Our medicines. Retrieved from [GlaxoSmithKline official website - section on medicines]
